ArticleScientific reports2025
Field trials of the novel varroacide, 1-allyloxy-4-propoxybenzene, against Varroa destructor in Western Canada.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spider venom peptides Ht1a and Gg1a are toxic to honeybee parasitenpj drug discovery · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Varroa destructor is an ectoparasite of western honey bees (Apis mellifera), substantially damaging managed colonies worldwide. Various chemical "varroacides" have been developed to help beekeepers combat infestations of these mites. Nevertheless, treatments may induce non-target toxicity in bees and humans, and their application can be laborious and hazardous. Moreover, widespread varroacide usage has seen the emergence of resistant mite populations, necessitating the need for new treatment options. The dialkoxybenzene, 1-allyloxy-4-propoxybenzene (codenamed 3c{3,6}), has previously been shown to induce paralysis and death of varroa in laboratory experiments, and capable of reducing varroa infestations in full-sized bee colonies. Our study sought to comprehensively investigate 3c{3,6} as a varroacide by optimizing dosages, treatment schedules and application methods across two sets of parallel experiments in Western Canada. Colonies treated with 3c{3,6} were compared to untreated negative controls and positive control colonies treated with the thymol-based commercial product, Thymovar. Across all experiments, 3c{3,6} had mite-killing efficacy comparable to Thymovar, being consistently greater than the untreated colonies, though efficacy varied between years. Treatment with 3c{3,6} did not impact food stores or bee populations. As treatment efficacy varied with dosage and application method, additional studies will be required to optimize 3c{3,6} treatment regimens for potential commercial use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.